Lv3
280 积分 2025-09-28 加入
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
1个月前
已完结
Property-Driven Design and Development of Lipids for Efficient Delivery of siRNA
1个月前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
2个月前
已完结
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2个月前
已完结
Converting TCR-based chimeric antigen receptor STAR into dual-specific targeting receptor for cancer immunotherapy
3个月前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
3个月前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
3个月前
已完结
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
3个月前
已关闭
Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy
3个月前
已完结
Ablation of FAS confers allogeneic CD3– CAR T cells with resistance to rejection by T cells and natural killer cells
3个月前
已完结
皖公网安备34019202002308
